Companies › Nuvectis Pharma
1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NXP900 SRC family kinase inhibitor | SRC | Phase 1 | EGFR Mutation Positive Non-small Cell Lung Cancer; Advanced Solid Tumor; ALK Positive | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07315113 | NXP900 | Phase 1 | EGFR Mutation Positive Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05873686 | NXP900 | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2027 |
| NCT07784959 | NXP900 | Phase 1 | ALK Positive | Oncology | Aug 2027 |
Cash of $141m on 2026-09-30; operating cash outflow about $49m a year; runway about 35 months at that burn, to Aug 2029
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Turning Point Therapeutics The Skin Center Dermatology Group Almirall
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.